Sohm, Inc. (SHMN) is a globally recognized pharmaceutical manufacturer that develops, manufactures, and distributes generic, private label, and Sohm-innovated pharmaceutical, cosmeceutical, and nutraceutical products. The company exports product worldwide, with a focus on distribution in emerging markets such as Africa, Latin America, and Southeast Asia.
In 2012, SHMN was voted the fastest growing generics prescription drug manufacturer at the 30th All India Conference of National Integrated Medical Association. Committed to being a global leader in improving the health and quality of people"s lives in every corner of the world, the company has U.S. headquarters in Buena Park, Calif., with international headquarters located in Ahmedabad, India, and several corporate offices located within the UK and China.
Research and development activities capitalize on the company"s expertise in numerous drug delivery technologies, including solid dosage form, oral-controlled and sustained releases semi-solid, liquid, oral transmucosal, transdermal, gel, injectable, and other drug delivery technologies, as well as the application of these technologies to proprietary drug forms.
To ensure regulatory compliance, SHMN continuously assesses and monitors the output of the existing quality systems, and application of evolving industry guidelines and regulations. Leveraging a global presence, an expanding drug portfolio that covers all major treatment categories, and a respected brand, SHMN is well positioned to continue its rapid growth.
www.sohm.com
In 2012, SHMN was voted the fastest growing generics prescription drug manufacturer at the 30th All India Conference of National Integrated Medical Association. Committed to being a global leader in improving the health and quality of people"s lives in every corner of the world, the company has U.S. headquarters in Buena Park, Calif., with international headquarters located in Ahmedabad, India, and several corporate offices located within the UK and China.
Research and development activities capitalize on the company"s expertise in numerous drug delivery technologies, including solid dosage form, oral-controlled and sustained releases semi-solid, liquid, oral transmucosal, transdermal, gel, injectable, and other drug delivery technologies, as well as the application of these technologies to proprietary drug forms.
To ensure regulatory compliance, SHMN continuously assesses and monitors the output of the existing quality systems, and application of evolving industry guidelines and regulations. Leveraging a global presence, an expanding drug portfolio that covers all major treatment categories, and a respected brand, SHMN is well positioned to continue its rapid growth.
www.sohm.com
